FGFR
39 programs · 38 companies
Programs
39
Companies
38
Active Trials
27
Targeting FGFR
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | T2DSMA | |
| Doxarasimod | Merck & Co | NDA/BLA | BCCSCLC | |
| AZN-7403 | AstraZeneca | Phase 2/3 | RBFTD | |
| Cevitinib | Regeneron | Phase 3 | Atopic Derm | |
| Tixatapinarof | Recursion | Approved | Asthma | |
| ABS-5770 | Absci | Preclinical | PsACKD | |
| 451-3882 | Chugai | Phase 1 | Breast Ca | |
| Sovafotisoran | UCB | NDA/BLA | NBLN | |
| NCI-IIT-878 | NCI | Approved | IgAN | |
| FRE-IIT-954 | Fred Hutch Cancer Ctr | Phase 2/3 | Endometrial Ca | |
| GIM-IIT-837 | GIMEMA | Phase 1 | RSV | |
| GRT-7895 | Gritstone | Phase 1 | Atopic Derm | |
| ATH-6254 | Athenex | Approved | PsA | |
| Tixazanubrutinib | Imago (Merck) | Phase 1 | NASH | |
| PBY-3950 | Puma Biotech | Phase 2 | CSUMM | |
| Ceviosocimab | Aerpio Pharmaceutics | NDA/BLA | ACCCF | |
| Adagrazumab | Imunon | Phase 1 | IgAN | |
| Datorasimod | Eliem Therapeutics | NDA/BLA | T2DPancreatic Ca | |
| Kematenlimab | Evofem Bio | Phase 3 | TTR AmyloidosisADHD | |
| Ivotapinarof | Proteus Digital | Approved | LN | |
| Tirazanubrutinib | Celltrion | Phase 3 | OCD | |
| IMM-5834 | Immunai | Phase 2 | ALSADPKD | |
| TER-1034 | Terray Ther | Phase 3 | Melanoma | |
| LMN-9194 | Liminal Bio | Approved | AMLBreast Ca | |
| FRE-IIT-854 | Fred Hutch | Phase 1/2 | Ewing Sarcoma | |
| ACL-6459 | Arcellx | Phase 3 | FLADPKD | |
| Nirarapivir | Natera | Phase 2 | RAMDS | |
| Elratuximab | Sensei Bio | Phase 1 | GIST | |
| Nidarelsin | Autolus Ther | Approved | ObesityADPKD | |
| RCE-2070 | Avita Medical | Phase 1/2 | Bladder CaHemophilia A | |
| NVC-9528 | Novocure | Phase 2 | Bladder Ca | |
| VBI-124 | VBI Vaccines | Phase 2/3 | Melanoma | |
| Doxazumab | VBI Vaccines | Phase 1/2 | MSLGS | |
| IDI-2657 | Idorsia | Approved | Melanoma | |
| Zenotuximab | Orphazyme | Phase 2/3 | RACRC | |
| Polamavacamten | Centogene | Phase 1/2 | Ovarian CaFabry | |
| ESC-2069 | Esco Lifesciences | Phase 1/2 | ADHDLN | |
| EGI-5078 | Egis Pharma | Phase 2 | PSPBCC | |
| Nirasacituzumab | Stada Arzneimittel | Phase 2/3 | HSPBC |